JAGIELSKA, Beata et al. Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS). Molecular and Cellular Therapies, [S.l.], v. 6, n. 1, jan. 2018. ISSN 2052-8426. Available at: <http://molcelltherapies.com/article/view/202>. Date accessed: 19 aug. 2018. doi: https://doi.org/10.26781/2052-8426-2018-02.